VANCOUVER, British Columbia, August 28, 2019 — Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”). Further to the Company’s news release of November 14, 2018, the sale of the Company’s 100% interest in Sechelt Organic Marijuana Inc. to Leis Industries Limited will not be proceeding. Further to the Company’s news release of February 12, 2019, the Company’s proposed acquisition of a commercial processing facility for hemp and cannabis products from T G Initiatives Ltd. will not be proceeding.
About Veritas Pharma
Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 100% owned subsidiary Cannevert Therapeutics Ltd. (“CTL“), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value and speed-to-market.
Veritas’ is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The Company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion-dollar markets.
Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: www.veritaspharmainc.com
On behalf of the Board of Directors
“Peter McFadden” Peter McFadden
Interim Chief Executive Officer & CFO
The CSE has not reviewed, nor approved or disapproved the content of this press release.